Tenderwize
Retour à la recherche

Non-exclusive drug discount agreement for Epoetin alfa and zeta

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Sep 30, 2027 · 398 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Epoetin alfa und Epoetin zeta (ATC-Code nach WHO: B03XA01)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

Actual purchase volumes are unknown and depend on prescription behavior, patient count, and pharmacy stockpiling. No mi...

The buyer reserves the right to terminate the open-house procedure early if exclusive discount agreements are signed. H...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2027
  • Supply of Epoetin alfa and Epoetin zeta pharmaceutical products under non-exclusive discount agreements
  • Open-House model allowing continuous participation by qualified pharmaceutical companies
Afficher le résumé complet

Non-exclusive drug discount agreement (Open-House model) for Epoetin alfa and zeta (ATC B03XA01) with AOK PLUS. No estimated value, no minimum volumes, and no exclusivity. Participation open continuously until 30 Sep 2027. Strict confidentiality and electronic submission via DTVP portal.

Risques

Actual purchase volumes are unknown and depend on prescription behavior, patient count, and pharmacy stockpiling. No mi...

The buyer reserves the right to terminate the open-house procedure early if exclusive discount agreements are signed. H...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Participants must be pharmaceutical entrepreneurs as defined in §4 Abs. 18 AMG

Administrative

  • Submit participation documents via DTVP portal; confidentiality obligations apply
  • First submission deadline: 30 April 2026; thereafter according to published schedule

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive drug discount agreement for Epoetin alfa and zeta

Open-House model for concluding non-exclusive discount agreements under §130a Abs. 8 SGB V for the active substances Epoetin alfa and Epoetin zeta (ATC B03XA01). No exclusive supply, no guaranteed volumes. Performance in Saxony and Thuringia, Germany.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

May 2026 - Sep 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Sep 30, 2027

Détails de la procédure

Date de publication
07 Apr 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
236720-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30